Skip to main content
. Author manuscript; available in PMC: 2014 Nov 22.
Published in final edited form as: N Engl J Med. 2014 May 22;370(21):2055–2056. doi: 10.1056/NEJMc1400883

Figure 1.

Figure 1

Fatal, Life-Threatening, and Non–Life-Threatening Occurrences of Anaphylaxis and Hypotension in Patients Who Received a First Dose of Peginesatide.

Deaths and life-threatening and non–life-threatening events were reported to the Food and Drug Administration.